Compare Apple Inc (AAPL) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance

Apple (AAPL) trades at $304.92, down 2.69% on the day, with a bearish technical signal and mixed sentiment. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $2.02 vs. $1.89, revenue growth to $416.16B in 2025, and robust cash flow. However, high valuation ratios like P/E of 35.35 and P/B of 41.84 pose concerns. Recent news highlights AI potential via a partnership with Alphabet's Gemini, but store closures and union disputes add volatility.

Outlook remains cautiously optimistic with a consensus price target of $337.63, implying 10.7% upside. Key opportunities include AI integration and device ecosystem strength, while risks involve competitive pressures, regulatory scrutiny, and reliance on iPhone sales. Institutional sentiment is positive with 63.6% buy ratings, but technical weakness near support at $301 requires monitoring.

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.